Immune-driven inflammatory angiogenesis is a crucial component in the pathogenesis of inflammatory bowel disease (IBD). Nevertheless, the underlying mechanisms are still poorly understood. This study aims to investigate the role of Transglutaminase 2 (TGM2) in inflammatory angiogenesis in IBD and its potential as a therapeutic target and biomarker. We performed an RNA-seq analysis integrated single-cell transcriptomic profiling on IBD biopsies to identify dysregulated genes. Additionally, we explored TGM2 contribution to angiogenesis and colitis under in vitro and in vivo conditions in Tgm2 knockout mouse and human intestinal microvascular endothelial cells (HIMECs). Serum TGM2 levels were measured by Enzyme-Linked Immunosorbent Assay. TGM2 expression was significantly upregulated in intestinal endothelial cells of IBD patients and colitis models. Tgm2 knockout and its inhibitor significantly attenuated intestinal colitis and angiogenesis in mice. In vitro, knockdown of TGM2 significantly suppressed tube formation, migration, and invasion of HIMECs. Mechanistically, inflammation-induced STAT1 activation promoted TGM2 expression, which subsequently interacted with vascular endothelial growth factor receptor 2 (VEGFR2) to drive its phosphorylation (Tyr1059, Tyr1214) and inflammatory angiogenesis. In patients of Crohn's Disease, serum TGM2 concentrations exhibited high diagnostic accuracy (AUC = 0.862) for assessing endoscopic activity. Our findings underscore the critical role of STAT1-TGM2-VEGFR2 axis in regulating angiogenesis during intestinal inflammation, suggesting that targeting TGM2 as a viable therapeutic candidate for vascular remodeling in chronic intestinal inflammation.
Background/Objectives: Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), is characterized by chronic gastrointestinal inflammatory diseases with complex etiology and remains a therapeutic challenge due to heterogeneous treatment responses. Opioids are widely used for analgesic management in IBD, yet the role of opioid signaling in IBD remains unclear. Methods: We employed single-cell RNA sequencing (scRNA-seq), bulk RNA sequencing, CellChat analysis, and transcription factor activity assessment to systematically investigate the roles and underlying mechanisms of opioid signaling-related genes in IBD. Results: We characterized opioid signaling-related genes in IBD at single-cell resolution and identified a novel subset of monocytes with a high expression level of opioid signaling-related genes (OpiHi monocytes). OpiHi monocytes were enriched in IBD tissues and served as a predominant source of tumor necrosis factor (TNF)-related signaling in the tissues of IBD. An inflammatory microenvironment in IBD drove the generation of OpiHi monocytes. Moreover, the prediction model based on OpiHi monocytes marker genes had robust predictive performance for the therapeutic response to anti-TNF therapy in IBD. Conclusions: This study provides novel insights into opioid signaling in IBD pathogenesis at the cellular level and establishes a reliable biomarker for precise management of anti-TNF therapy.
Single-cell RNA sequencing can resolve cellular heterogeneity but is sensitive to heterotypic doublets and often requires expert-driven preprocessing and annotation. We developed single cell utility matrices processing engine (scUmaper), an R/Seurat-native workflow that integrates quality control, biologically grounded doublet filtering, and marker-library-based cell-type annotation. scUmaper codifies lineage-marker incompatibility rules and applies global clustering followed by within-lineage re-clustering to reveal anomalous subclusters with implausible cross-lineage co-expression. Across six public human organ datasets, scUmaper removed additional high-confidence heterotypic doublets that were retained by simulation-based approaches and achieved annotation agreement comparable to or higher than commonly used R-based baselines, with competitive runtime. Stress tests with simulated ambient RNA contamination and reduced sequencing depth showed stable outputs under moderate degradation. scUmaper provides an interpretable and extensible framework that lowers barriers for reproducible single-cell RNA sequencing (scRNA-seq) analysis.